Display options
Cite
Leary JA, Edwards BG, Houghton CR, et al. Amplification of HER-2/neu oncogene in human ovarian cancer. Int J Gynecol Cancer. 1992;2(6):291-4doi: 10.1046/j.1525-1438.1992.02060291.x.
Leary, J. A., Edwards, B. G., Houghton, C. R., Kefford, R. F., & Friedlander, M. L. (1992). Amplification of HER-2/neu oncogene in human ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2(6), 291-4. https://doi.org/10.1046/j.1525-1438.1992.02060291.x
Leary, J A, et al. "Amplification of HER-2/neu oncogene in human ovarian cancer." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 2,6 (1992): 291-4. doi: https://doi.org/10.1046/j.1525-1438.1992.02060291.x
Leary JA, Edwards BG, Houghton CR, Kefford RF, Friedlander ML. Amplification of HER-2/neu oncogene in human ovarian cancer. Int J Gynecol Cancer. 1992 Nov;2(6):291-4. doi: 10.1046/j.1525-1438.1992.02060291.x. PMID: 11576271.
Copy Download .nbib Format: NLM
Share it on

Int J Gynecol Cancer. 1992 Nov;2(6):291-4. doi: 10.1046/j.1525-1438.1992.02060291.x.

Amplification of HER-2/neu oncogene in human ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

J A Leary, B G Edwards, C R Houghton, R F Kefford, M L Friedlander

Affiliations

  1. Departments of Medical Oncology and Obstetrics and Gynaecology, University of Sydney, Westmead Centre, Westmead, NSW 2145, and Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW 2031, Australia.

PMID: 11576271 DOI: 10.1046/j.1525-1438.1992.02060291.x

Abstract

Amplification and/or increased expression of the HER-2/neu oncogene has been reported to occur in ovarian tumors and possibly to correlate with biologic behavior and prognosis. The frequency with which amplification is reported to occur is quite variable ranging from 0-30% in different series and this variability is probably accounted for by technical and methodologic factors. The variability and lack of reproducibility has raised questions about the usefulness of assessing amplification of the HER-2/neu oncogene and in particular its clinical relevance. In this study by using strict criteria for amplification and using multiple controls we could demonstrate unequivocal amplification of the HER-2/neu oncogene by Southern blot analysis in only 11% of malignant ovarian tumors. The potential pitfalls with the techniques used to detect HER-2/neu oncogene amplification and overexpression are reviewed and possible ways to overcome some of the problems are suggested.

Publication Types